KLRS Q2 2020 Earnings — Kalaris Therapeutics Inc Revenue & Financial Results | Market Cap Arena

KLRSKalaris Therapeutics Inc

$180M

Q2 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$19,000

Operating Income

-$12M

Net Income

-$12M

EPS (Diluted)

$-4.11

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$11M

Free Cash Flow

-$11M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$118M

Total Liabilities

$16M

Stockholders' Equity

$102M

Cash & Equivalents

$78M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$19,000	$0	—
Operating Income	-$12M	-$6M	-104.4%
Net Income	-$12M	-$5M	-119.4%